Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies Among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Feb 10

PMID 38337457

Authors

Puneet Misra

Guruprasad R Medigeshi

Shashi Kant

Abhishek Jaiswal

Mohammad Ahmad

Anisur Rahman

Randeep Guleria

Sanjay Kumar Rai

Trideep Jyoti Deori

Suprakash Mandal

Gaurav Gongal

Mohan Bairwa

Partha Haldar

Rakesh Kumar

Neha Garg

Affiliations

Soon will be listed here.

Abstract

This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a period of 1 year. One hundred laboratory-confirmed COVID-19 cases were recruited. Serum samples of the participants were collected within three months from the date of the positive COVID-19 report. The participants were prospectively followed up every three months for symptoms and the collection of blood samples for three additional rounds. The presence of anti-SARS-CoV-2 antibodies (IgA, IgG, and IgM antibodies), anti-receptor binding domain antibodies (anti-RBD), and neutralizing antibodies were measured. Median plaque reduction neutralization test (PRNT) titers showed a rising trend in the first three rounds of follow-up. The quantitative anti-receptor binding domain ELISA (QRBD) values showed a declining trend in the initial three rounds. However, both the PRNT titers and QRBD values showed significantly higher values for the fourth round of follow-up. Total antibody (WANTAI) levels showed an increasing trend in the initial three rounds (statistically significant). Neutralizing antibodies showed an increasing trend. The anti-receptor binding domain antibodies showed a decreasing trend. Neutralizing antibodies and anti-RBD antibodies persisted in the majority.

References

Breton G, Mendoza P, Hagglof T, Oliveira T, Schaefer-Babajew D, Gaebler C . Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med. 2021; 218(4). PMC: 7845919. DOI: 10.1084/jem.20202515. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View

Misra P, Kant S, Guleria R, Rai S, Jaiswal A, Mandal S . Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India. Vaccines (Basel). 2022; 10(8). PMC: 9412620. DOI: 10.3390/vaccines10081312. View

Mesquita R, Silva Junior L, Santana F, Oliveira T, Alcantara R, Arnozo G . Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr. 2020; 133(7-8):377-382. PMC: 7689634. DOI: 10.1007/s00508-020-01760-4. View

Wang M, Zhao R, Gao L, Gao X, Wang D, Cao J . SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020; 10:587269. PMC: 7723891. DOI: 10.3389/fcimb.2020.587269. View

Gaebler C, Wang Z, Lorenzi J, Muecksch F, Finkin S, Tokuyama M . Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591(7851):639-644. PMC: 8221082. DOI: 10.1038/s41586-021-03207-w. View

Lumley S, Wei J, ODonnell D, Stoesser N, Matthews P, Howarth A . The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. Clin Infect Dis. 2021; 73(3):e699-e709. PMC: 7929225. DOI: 10.1093/cid/ciab004. View

Chen W, Hotez P, Bottazzi M . Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020; 16(6):1239-1242. PMC: 7482854. DOI: 10.1080/21645515.2020.1740560. View

10.

Lau E, Tsang O, Hui D, Kwan M, Chan W, Chiu S . Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021; 12(1):63. PMC: 7782739. DOI: 10.1038/s41467-020-20247-4. View

11.

Ravi N, Cortade D, Ng E, Wang S . Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron. 2020; 165:112454. PMC: 7368663. DOI: 10.1016/j.bios.2020.112454. View

12.

Lau E, Hui D, Tsang O, Chan W, Kwan M, Chiu S . Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine. 2021; 41:101174. PMC: 8556690. DOI: 10.1016/j.eclinm.2021.101174. View

13.

Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z . A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMC: 7094943. DOI: 10.1038/s41586-020-2008-3. View

14.

Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F . Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020; 71(15):778-785. PMC: 7184472. DOI: 10.1093/cid/ciaa310. View

15.

Haveri A, Ekstrom N, Solastie A, Virta C, Osterlund P, Isosaari E . Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021; 51(12):3202-3213. PMC: 8646652. DOI: 10.1002/eji.202149535. View

16.

Pradenas E, Trinite B, Urrea V, Marfil S, Avila-Nieto C, Rodriguez de la Concepcion M . Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med. 2021; 2(3):313-320.e4. PMC: 7847406. DOI: 10.1016/j.medj.2021.01.005. View

17.

Hall V, Foulkes S, Charlett A, Atti A, Monk E, Simmons R . SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021; 397(10283):1459-1469. PMC: 8040523. DOI: 10.1016/S0140-6736(21)00675-9. View

18.

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X . Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020; 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z. View

19.

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F . Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021; 27(5):917-924. DOI: 10.1038/s41591-021-01318-5. View

20.

Dan J, Mateus J, Kato Y, Hastie K, Yu E, Faliti C . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529). PMC: 7919858. DOI: 10.1126/science.abf4063. View